PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Xia, Y. ; Cheng, X. ; Blossey, C.K. ; Wisskirchen, K. ; Esser, K. ; Protzer, U.

Secreted interferon-inducible factors restrict hepatitis B and C virus entry in vitro.

J. Immunol. Res. 2017:4828936 (2017)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Interferon-α (IFN-α) has been used for more than 20 years as the first-line therapy for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, because it has a number of antiviral effects. In this study, we describe a novel mode of its antiviral action. We demonstrate that the supernatant from IFN-α-treated cultured cells restricted HBV and HCV infection by inhibiting viral entry into hepatoma cells. The factors contained in the supernatant competed with the virus for binding to heparan glycosaminoglycans-the nonspecific attachment step shared by HBV and HCV. Secreted factors of high molecular mass that bind to heparin columns elicited the antiviral effect. In conclusion, IFN-α is able to induce soluble factors that can bind to heparan glycosaminoglycans thus leading to the inhibition of viral binding.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
3.276
1.040
13
18
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Surface Heparan-sulfate; Humanized Mice; Initial Interaction; Envelope Protein; Dengue Virus; Infection; Replication; Binding; Cells; Identification
Sprache englisch
Veröffentlichungsjahr 2017
HGF-Berichtsjahr 2017
ISSN (print) / ISBN 2314-8861
e-ISSN 2314-7156
Zeitschrift Journal of Immunology Research
Quellenangaben Band: 2017, Heft: , Seiten: , Artikelnummer: 4828936 Supplement: ,
Verlag Hindawi
Verlagsort New York, NY
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Virology (VIRO)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-502700-003
PubMed ID 28367455
DOI 10.1155/2017/4828936
WOS ID WOS:000398697100001
Scopus ID 85015955903
Erfassungsdatum 2017-06-08
[➜Korrektur melden]